摘要
目的探讨乳腺癌患者组织人类表皮生长因子受体2(Her-2)与细胞增殖核抗原Ki-67(Ki-67)表达和血清肿瘤抗原153(CA153),血清肿瘤抗原125(CA125),癌胚抗原(CEA)水平的相关性。方法选取2017年1月至2019年12月淮安市妇幼保健院收治的80例乳腺癌患者作为研究对象,采用免疫组织化学方法分为Her-2(+)组和Her-2(-)组,Her-2(+)组采用全自动化学发光分析方法,Her-2(-)组采用全自动化学发光分析方法。对两组患者血清CA153、CA125、CEA水平和癌组织中Ki-67表达情况的变化进行回顾性分析。结果Her-2(+)组乳腺癌患者Ki-67表达高于Her-2(-)组,差异有统计学意义(P<0.05)。两组的CA153、CA125、CEA水平比较,差异无统计学意义(P>0.05)。Ki-67≤20%的表达率为20%(16/80),Ki-67>20%表达率为80%(64/80),Ki-67高表达与患者Her-2表达呈正相关(P<0.05)。结论乳腺癌患者血清CA153、CA125、CEA水平与Her-2表达无关,然而,Ki-67高表达与Her-2表达呈正相关。
Objective To explore the correlation between the expression of human epidermal growth factor receptor 2(Her-2)and proliferating cell nuclear antigen Ki-67(Ki-67)and the levels of serum tumor antigen 153(CA153),serum tumor antigen 125(CA125),carcinoembryonic antigen(CEA)in patient with breast cancer.Methods Eighty patients with breast cancer treated in Huaian Maternal and Child Health Care Hospital from January 2017 to December 2019 were selected as research subjects.Patients were divided into the Her-2(+)group and the Her-2(-)group according to the immunohistochemical method.Automatic chemiluminescence analysis method was adopted in the Her-2(+)group and the Her-2(-)group.The serum levels of CA153,CA125,and CEA and the expression of Ki-67 in cancer tissues were retrospectively analyzed.Results The expression of Ki-67 of patients with breast cancer in the Her-2(+)group was higher than that in the Her-2(-)group,with statistically significant difference(P<0.05).There were no statistically significant differences in the levels of CA153,CA125 and CEA between the two groups(P>0.05).The expression rate of Ki-67≤20%was 20%(16/80),and the expression rate of Ki-67>20%was 80%(64/80).The high expression of Ki-67 was positively correlated with the expression of Her-2 in patients(P<0.05).Conclusion The serum levels of CA153,CA125 and CEA in patients with breast cancer have nothing to do with the expression of Her-2.However,the high expression of Ki-67 is positively correlated with the expression of Her-2.
作者
吕艳关
孙晓冲
朱婷
LYU Yan-guan;SUN Xiao-chong;ZHU Ting(Clinical Laboratory,Huaian Maternal and Child Health Care Hospital Affiliated to Yangzhou University,Jiangsu Province,Huaian 223002,China)
出处
《中国当代医药》
CAS
2021年第26期220-222,共3页
China Modern Medicine
基金
江苏省妇幼健康科研项目(F201952)
江苏省淮安市卫生健康科研立项项目(HAWJ201920)
江苏省淮安市“天医星”医学检验重点实验室课题(HAP202004)。
作者简介
吕艳关(1981-),男,江苏淮安人,硕士,副主任技师,科主任,研究方向:临床免疫学诊断;通讯作者:朱婷(1991-),女,江苏泗阳人,硕士,研究方向:临床检验诊断学。
